Form D — Antares Therapeutics, Inc.
0002059043-25-000002 · filed May 15, 2025
Offering amounts describe securities offered; amounts sold are issuer-reported as of each filing. Amendments can repeat earlier amounts. We do not add these figures into a capital-raised total. Missing amounts are not zero. Data coverage and methodology · How to interpret the amounts.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Reported offering amount
- $136,650,000
- Reported amount sold
- $30,000,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Antares Therapeutics, Inc.
- CIK
- 2059043
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2025
- Address
- ONE WINTHROP SQUARE, SUITE 400
BOSTON, MA 02110 - Phone
- 781-288-5760
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Adam Friedman · Executive OfficerBoston, MA Find on LinkedIn ↗
-
Shelley Chu · DirectorBoston, MA Find on LinkedIn ↗
-
Keith Flaherty · DirectorBoston, MA Find on LinkedIn ↗
-
Jeffrey Albers · DirectorBoston, MA Find on LinkedIn ↗
-
Brian Piper · Executive OfficerBoston, MA Find on LinkedIn ↗
-
Andrew Fedder · Executive OfficerBoston, MA Find on LinkedIn ↗
-
Jean-Francois Formela · DirectorBoston, MA Find on LinkedIn ↗
-
Menelas N. Pangalos · DirectorBoston, MA Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗